| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/05/2009 | US7527792 Arg-arg-leu-ser-tyr-ser-arg-arg-arg-phe decapeptide bonded to drug such as doxorubicin via maleimide derivative linkage; preventing chemoresistance or drug resistance; gene expression inhibition of multidrug resistance gene |
| 05/05/2009 | US7527791 Humanized anti-TGF-beta antibodies |
| 05/05/2009 | US7527790 Genetic engineered protein; screening, controlling gene expression |
| 05/05/2009 | US7527789 Use of a preparation based on an antibody directed against a tumor-associated glycosylation |
| 05/05/2009 | US7527788 Purified antibody, monoclonal antibody, or polyclonal antibody that binds to DES protein of Mycobacterium tuberculosis; medical diagnosis |
| 05/05/2009 | US7527786 Monoclonal anti-idiotypic antibody; antitumor agents; anticarcinogenic agents; antiproliferative agents; immunotherapy; hormone antagonist therapy |
| 05/05/2009 | CA2610100A1 Methods and compositions for treating and preventing malaria |
| 05/05/2009 | CA2606624A1 Methods and compositions for treating and preventing malaria (2) |
| 05/05/2009 | CA2253790C Methods of enhancing anti-tumour immunity in a mammal |
| 05/05/2009 | CA2149298C Flk-1 is a receptor for vascular endothelial growth factor |
| 05/05/2009 | CA2146647C Treatment of autoimmune and inflammatory disorders |
| 05/01/2009 | CA2607771A1 Humanized anti-venezuelan equine encephalitis virus recombinant antibody |
| 05/01/2009 | CA2606828A1 Methods of assessing and treating pulmonary disease |
| 04/30/2009 | WO2009055783A2 Anti-pcsk9 and methods for treating lipid and cholesterol disorders |
| 04/30/2009 | WO2009055729A1 Compositions and methods for treating inflammation |
| 04/30/2009 | WO2009055711A2 Anti-rsv g protein antibodies |
| 04/30/2009 | WO2009055688A2 Vaccine targets and delivery systems for cryptosporidium |
| 04/30/2009 | WO2009055669A2 Monoclonal antibodies against activated and unactivated protein c |
| 04/30/2009 | WO2009055656A2 Vectors, host cells, and methods of production and uses |
| 04/30/2009 | WO2009055613A2 Inhibition of urokinase-type plasminogen activator (upa) activity |
| 04/30/2009 | WO2009055417A1 Compositions for detecting antibodies to babesia microti and methods of uses thereof |
| 04/30/2009 | WO2009055343A2 Fully human anti-vegf antibodies and methods of using |
| 04/30/2009 | WO2009055074A2 Erbb2 binding proteins and use thereof |
| 04/30/2009 | WO2009054873A2 Anti-rantes antibodies and methods of use thereof |
| 04/30/2009 | WO2009054863A2 Human antibodies that bind cd19 and uses thereof |
| 04/30/2009 | WO2009054858A1 Methods and compositions for the treatment and prevention of staphylococcus aureus infections |
| 04/30/2009 | WO2009054813A1 Method of delivering an anti-cancer agent to a cell |
| 04/30/2009 | WO2009054556A1 Method for preparation of therapeutic b cells against autoimmune diseases which are induced by autoimmune cytotoxicity |
| 04/30/2009 | WO2009054537A1 PEPTIDE VACCINE USING MIMIC MOLECULE OF AMYLOID β-PEPTIDE |
| 04/30/2009 | WO2009054471A1 Immune response inducer |
| 04/30/2009 | WO2009054470A1 Immune response inducer and use thereof |
| 04/30/2009 | WO2009054435A1 Polypeptide having enhanced effector function |
| 04/30/2009 | WO2009054433A1 Cell for use in the production of exogenous protein, and production process using the cell |
| 04/30/2009 | WO2009054332A1 Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| 04/30/2009 | WO2009054001A1 A pharmaceutical composition and a process thereof |
| 04/30/2009 | WO2009053987A1 Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf) |
| 04/30/2009 | WO2009053844A1 Synthetic antigenic peptides and lipopeptides derived fro mycobacterium avium subsp. paratuberculosis |
| 04/30/2009 | WO2009053723A1 Small protective epitopes of the yersinia pestis v antigen and dna vaccines encoding these |
| 04/30/2009 | WO2009053696A1 Monoclonal antibody for app |
| 04/30/2009 | WO2009053637A2 Anti-ricin antibody |
| 04/30/2009 | WO2009053604A2 Influenza virus haemagglutinin-specific monoclonal antibodies |
| 04/30/2009 | WO2009053601A2 Method for preparing a vaccine composition comprising at least one antigen and at least one adjuvant |
| 04/30/2009 | WO2009053514A1 Method for the diagnosis and treatment of diseases which develop with alteration of kinase p38, elements necessary therefor and applications thereof |
| 04/30/2009 | WO2009053512A1 Porcine torovirus proteins n, m and he, method for production thereof and uses thereof in diagnosis and treatment of porcine torovirus |
| 04/30/2009 | WO2009053481A1 Compositions and methods for modulating nk and t cell trafficking |
| 04/30/2009 | WO2009053442A1 Use of trkb antibodies for the treatment of respiratory disorders |
| 04/30/2009 | WO2009053109A1 Antigen-specific t-cell preparations from bone marrow |
| 04/30/2009 | WO2009053098A1 Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders |
| 04/30/2009 | WO2009053038A2 Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor |
| 04/30/2009 | WO2009052830A1 Novel antibody therapies |
| 04/30/2009 | WO2009052629A1 Compositions and methods for enhancing immune response |
| 04/30/2009 | WO2009052628A1 Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof |
| 04/30/2009 | WO2009052623A1 Therapeutic and diagnostic methods using tim-3 |
| 04/30/2009 | WO2009052617A1 Treatment regime for proliferative disorders |
| 04/30/2009 | WO2009052572A1 Streptococcus m protein, immunogenic fragments, nucleic acids and methods of use |
| 04/30/2009 | WO2009052555A1 Immunogenic protein pas n 1 from bahia grass pollen |
| 04/30/2009 | WO2009035494A3 Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease |
| 04/30/2009 | WO2009033742A3 Streptococcus pneumoniae vaccines |
| 04/30/2009 | WO2009033009A3 Antibodies against flagellin and uses thereof |
| 04/30/2009 | WO2009032978A3 Compositions and methods for diagnosing and treating urinary tract infections |
| 04/30/2009 | WO2009032913A3 Thermal inactivation of rotavirus |
| 04/30/2009 | WO2009022216A9 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles |
| 04/30/2009 | WO2009022156A3 Peptides for desensibilization against allergens |
| 04/30/2009 | WO2009019312A3 Anti cd37 antibodies |
| 04/30/2009 | WO2009016639A3 Multimeric multiepitope influenza vaccines |
| 04/30/2009 | WO2009013619A3 The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases |
| 04/30/2009 | WO2009010957A3 Heparanase c-terminal domain, sequences derived therefrom, substances directed against said domain and uses thereof as modulators of heparanase biological activity |
| 04/30/2009 | WO2009006301A4 Protein stabilization |
| 04/30/2009 | WO2008155387A3 Anti-igf antibodies that bind to igf-1 and igf-2 but not to insulin |
| 04/30/2009 | WO2008140487A3 Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use |
| 04/30/2009 | WO2008134445A3 Platelet activation receptor clec-2: compositions and uses thereof |
| 04/30/2009 | WO2008132608A3 Combined use of egf pathway inhibitors and differentiation promoting compounds |
| 04/30/2009 | WO2008129559A4 Antigenic polysaccharides and process for their preparation |
| 04/30/2009 | WO2008094969A3 Combination therapy with angiogenesis inhibitors |
| 04/30/2009 | WO2008094176A3 Ilt3 binding molecules and uses therefor |
| 04/30/2009 | WO2008085794A3 Methods and compositions related to clot binding compounds |
| 04/30/2009 | WO2008011710A8 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 04/30/2009 | WO2008001379A3 Activated myeloid cells for promoting tissue repair and detecting damaged tissue |
| 04/30/2009 | WO2007148326A3 Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders |
| 04/30/2009 | WO2007056352A3 Compositions and methods for controlling tissue factor signaling specificity |
| 04/30/2009 | WO2007053589A3 Immunoassay of fragments of insulin-like growth factor binding proteins |
| 04/30/2009 | WO2007029262A3 Compositions and methods using same for the detection of viruses |
| 04/30/2009 | WO2007027916A9 Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| 04/30/2009 | WO2007019406A3 Methods for treating and detecting beta-cell disease |
| 04/30/2009 | WO2007002080A3 Eya2s as modifiers of the pten/akt pathway and methods of use |
| 04/30/2009 | WO2006138478A3 Stimulation of toll-like receptors on t cells |
| 04/30/2009 | WO2006133107A3 Specific binding sites in collagen for integrins and use thereof |
| 04/30/2009 | WO2006122144A3 Methods and compositions for pdgf-d activation and inhibition |
| 04/30/2009 | WO2006113546A3 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| 04/30/2009 | WO2006083964A3 Modified fusion molecules for treatment of allergic disease |
| 04/30/2009 | WO2006047638A3 Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease |
| 04/30/2009 | WO2006041906A3 Methods and compositions for immunizing against pseudomonas infection |
| 04/30/2009 | WO2005120583A3 Method for preventing or treating cardiac hypertrophy |
| 04/30/2009 | WO2004071436A3 The use of gcc ligands |
| 04/30/2009 | US20090111172 isolated polypeptide is immobilized on an immunosorbent surface of ELISA plate for determining whether a mouse is infected with murine norovirus-1 by determining presence, absence or quantity of antibody against MNV-1 a sample of a mouse |
| 04/30/2009 | US20090110739 Targeted cancer chemotherapy using synthetic nanoparticles |
| 04/30/2009 | US20090110717 Transmucosal composition |
| 04/30/2009 | US20090110702 Mesothelin Vaccines and Model Systems and Control of Tumors |
| 04/30/2009 | US20090110701 T-cell modulation |
| 04/30/2009 | US20090110700 Acellular immunogenic compositions and acellular vaccine compositions against bacillus anthracis |